NASDAQ:CKPT - Checkpoint Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.49 -0.09 (-3.49 %)
(As of 07/18/2018 08:13 AM ET)
Previous Close$2.58
Today's Range$2.45 - $2.59
52-Week Range$2.25 - $10.50
Volume34,101 shs
Average Volume60,807 shs
Market Capitalization$82.60 million
P/E Ratio-2.49
Dividend YieldN/A
Checkpoint Therapeutics logoCheckpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC. Its pipeline consists of glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. The company is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein, and poly polymerase. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Receive CKPT News and Ratings via Email

Sign-up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio4.84
Quick Ratio4.84


Trailing P/E Ratio-2.49
Forward P/E Ratio-1.83
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.73 million
Price / Sales46.07
Cash FlowN/A
Price / CashN/A
Book Value$0.59 per share
Price / Book4.22


EPS (Most Recent Fiscal Year)($1.00)
Net Income$-22,670,000.00
Net Margins-1,967.93%
Return on Equity-122.20%
Return on Assets-96.27%


Outstanding Shares32,010,000
Market Cap$82.60

The Truth About Cryptocurrencies

Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions

What is Checkpoint Therapeutics' stock symbol?

Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics Inc (NASDAQ:CKPT) posted its quarterly earnings data on Thursday, May, 10th. The company reported ($0.35) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.13. The company earned $0.34 million during the quarter. Checkpoint Therapeutics had a negative net margin of 1,967.93% and a negative return on equity of 122.20%. View Checkpoint Therapeutics' Earnings History.

What price target have analysts set for CKPT?

1 Wall Street analysts have issued 12 month target prices for Checkpoint Therapeutics' shares. Their predictions range from $11.00 to $11.00. On average, they expect Checkpoint Therapeutics' share price to reach $11.00 in the next year. This suggests a possible upside of 341.8% from the stock's current price. View Analyst Ratings for Checkpoint Therapeutics.

What is the consensus analysts' recommendation for Checkpoint Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Checkpoint Therapeutics' key competitors?

Who are Checkpoint Therapeutics' key executives?

Checkpoint Therapeutics' management team includes the folowing people:
  • Mr. James F. Oliviero III, CEO & Pres (Age 42)
  • Mr. William Garrett Gray, VP of Fin. & Accounting, Principal Financial Officer and Corp. Sec. (Age 31)
  • Ms. Robyn M. Hunter, Corp. Sec. (Age 56)

Has Checkpoint Therapeutics been receiving favorable news coverage?

News coverage about CKPT stock has trended positive on Wednesday, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Checkpoint Therapeutics earned a daily sentiment score of 0.36 on Accern's scale. They also gave news headlines about the company an impact score of 46.64 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Checkpoint Therapeutics' stock price today?

One share of CKPT stock can currently be purchased for approximately $2.49.

How big of a company is Checkpoint Therapeutics?

Checkpoint Therapeutics has a market capitalization of $82.60 million and generates $1.73 million in revenue each year. The company earns $-22,670,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Checkpoint Therapeutics employs 6 workers across the globe.

How can I contact Checkpoint Therapeutics?

Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]

MarketBeat Community Rating for Checkpoint Therapeutics (NASDAQ CKPT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  140
MarketBeat's community ratings are surveys of what our community members think about Checkpoint Therapeutics and other stocks. Vote "Outperform" if you believe CKPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CKPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.